Waleed Ghanima, MD

Professor
Østfold Hospital Foundation

Professor Waleed Ghanima is Head of Research and Consultant Hematologist at Østfold Hospital, Norway. He is also Professor at the Institute of Clinical Medicine at the University of Oslo, Norway. Professor Ghanima gained his medical degree from the College of Medicine, University of Baghdad, Iraq. Professor Ghanima’s main research field is venous thrombosis and immune thrombocytopenia (ITP). He is a member of several professional societies and was President of the Norwegian Society of Haematology between 2013 and 2017. He has published over 150 articles in national and international peer-reviewed journals including NEJM, Lancet, Blood, and Thrombosis and Haemostasis.

Presentation(s):

• SS 11.3 - Challenges Treating Patients With ITP

  Sunday, July 10, 2022
  1:37 PM – 1:54 PM

• SS 11.5 - Q&A

  Sunday, July 10, 2022
  2:11 PM – 2:25 PM

• PB0596 - Anti-SARS-CoV-2 vaccines do not induce a hypercoagulable state in healthy individuals

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0971 - Clinical and echocardiographic variables associated with residual perfusion defects after pulmonary embolism

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• SS 23.6 - Immune Thrombocytopenia: A Numbers Game?

  Tuesday, July 12, 2022
  1:15 PM – 2:30 PM

• SS 23.1 - Welcome

  Tuesday, July 12, 2022
  1:15 PM – 1:20 PM

• SS 23.4 - 1, 2, 3: Treatment Lines

  Tuesday, July 12, 2022
  2:00 PM – 2:20 PM

• SS 23.5 - Closing

  Tuesday, July 12, 2022
  2:20 PM – 2:30 PM

• OC 60.3 - Cost-effectiveness of performing reference ultrasonography in patients with deep vein thrombosis

  Tuesday, July 12, 2022
  3:15 PM – 3:30 PM

• PB1327 - Health-Related Quality of Life and physical capacity in patients with residual perfusion defects after pulmonary embolism

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1328 - The Venous Thrombosis Registry in Østfold Hospital (The TROLL registry); design and cohort description

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 73.1 - Updated Main Study Period and Long-Term Extension (LTE) Results With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Immune Thrombocytopenia (ITP)

  Wednesday, July 13, 2022
  10:15 AM – 10:30 AM